Gray matter increases in fronto-parietal regions of depression patients with aripiprazole monotherapy
An exploratory study

Chien-Han Lai, MD, PhD\textsuperscript{a,b,c}, Yu-Te Wu, PhD\textsuperscript{b,c,d,*}, Cheng-Yu Chen, MD\textsuperscript{e}, Yi-Cheng Hou, MSc\textsuperscript{f,g}

Abstract

We investigated the treatment effects of aripiprazole monotherapy in first-episode medication-naïve patients with major depressive disorder (MDD). The accompanying changes in the gray matter volume (GMV) were also explored.

Fifteen patients completed the trial and received structural scans by 3-Tesla magnetic resonance imaging at baseline and partially responding state (sixth week). To account for the test–retest bias, 27 healthy controls were scanned twice within 6 weeks. We utilized optimized voxel-based morphometry with different comparisons between groups.

The partially responding patients with MDD had greater GMV in left middle frontal gyrus and left superior parietal gyrus when compared with baseline. However, they had decreases in the GMV of right orbitofrontal gyrus and right inferior temporal gyrus after response. The partially responding patients with MDD still had residual GMV deficits in right superior frontal gyrus when compared with controls. However, the lack of second patient group without aripiprazole intervention would be a significant limitation to interpret the aripiprazole-specific effects on GMV.

The changes in the GMV of the fronto-parieto-temporal regions and residual GMV deficits in the superior frontal gyrus might represent “state-dependent brain changes” and “residual-deficit brain regions,” respectively, for aripiprazole monotherapy in MDD.

Abbreviations: GMV = gray matter volume, HARS = Hamilton Rating Scales for Anxiety, HDRS = Hamilton Rating Scales for Depression 17-item, IOFG = inferior orbitofrontal gyrus, ITG = inferior temporal gyrus, MDD = major depressive disorder, MFG = middle frontal gyrus, MR = magnetic resonance, QIDS-SR16 = Quick Inventory for Depressive Symptoms-Self Rating 16-Item version, SFG = superior frontal gyrus, SPG = superior parietal gyrus, VBM = voxel-based morphometry.

Keywords: aripiprazole, gray matter volume, major depressive disorder, middle frontal gyrus, superior parietal gyrus
1. Introduction

Major depressive disorder (MDD) was associated with social and occupational impairments in many dimensions. The untreated depression usually will enter a deteriorating course. The treatment of MDD is an important issue for clinical practices. The typical therapy for MDD mostly focuses on the antidepressants. For the monotherapy of atypical antipsychotics in MDD, it remained controversial and inconclusive even with proved efficacy in augmentation therapy.

The brain structure is an important issue for the pathophysiology in MDD. The voxel-based morphometry (VBM) studies[1–3] and meta-analysis[4] revealed fronto-limbic deficits in gray matter volume (GMV) of MDD patients. The meta-analysis also addressed the connection between prefrontal–limbic GMV deficits and medication-naive depression.[5] GMV reductions in the frontal regions play a major role for neuropsychological impairments in MDD.[1,5–7] GMV of the superior frontal cortex is related to cognitive impairments of depressed patients[8] and inferior frontal cortex may reflect disorder-specific symptom clusters for MDD.[1] These results suggested that the patients with MDD probably have frontal-specific pattern of neuroanatomical deficits, either in status of partial response or untreated.

The medication therapy for MDD in the field of neuroanatomical plasticity and modulation has been an intriguing issue for research. Our previous reports showed the possible association of antidepressants with structural changes in the fronto–limbic network of MDD comorbid with panic disorder.[2,6] The recent report of MDD also found that the remitted patients had significant increases in GMV of right orbitofrontal cortex and temporal cortex after antidepressant treatment.[10] Similar increases in the GMV of dorsolateral prefrontal cortex were also replicated.[11] However, no evidence for GMV increases in depressed patients has also been reported in several studies after treatment or after remission.[12,13] In addition to the antidepressants, the augmentation role of atypical antipsychotics for MDD treatment has been emphasized in recent years, and more evidences support the augmentation efficacy of aripiprazole in MDD.[14,15] The therapeutic mechanisms probably include aripiprazole’s unique effects of partial agonism at dopamine D2, D3, and serotonin 5-HT1A receptors, and antagonism at serotonin 5-HT2A receptors.[16] However, aripiprazole monotherapy for MDD has not been addressed much in modulating effects on the brain. There are only several case reports with the findings of GMV and subcortical changes after aripiprazole monotherapy.[17–19] The therapeutic effects of aripiprazole monotherapy and related effects in the GMV for MDD remain unclear. In the current study, a 6-week monotherapy of aripiprazole in patients with MDD would be implemented. In addition, different comparisons of GMV between patients and controls at baseline and sixth week will be done, which might clarify the unresolved issue.

From the above literature review, we hypothesized that first-episode, medication-naive patients with MDD would have partial response after aripiprazole monotherapy. The reason to choose aripiprazole in this study was purely scientific interest in depression pathology. In addition, MDD patients might have GMV deficits in the fronto–limbic regions, which would be improved after clinical responses (state-dependent brain changes). However, residual deficits in the GMV would persist even with partial response (residual-deficit brain regions). We would use optimized VBM method to estimate the differences in GMV between patients and controls at baseline and at sixth week to identify the “state-dependent brain changes” and “residual-deficit brain regions” for the aripiprazole monotherapy in MDD.

2. Methods

2.1. Participants

The selection criteria for the patients were as follows: first-episode, medication-naive (psychotropic medication) outpatients with a pure MDD diagnosis made on the basis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria using the Structured Clinical Interview for DSM-IV[20]; no comorbid mental disorders or significant medical illnesses for life time; severity of MDD was at least moderate: Clinician Global Impression of Severity[21] >4; the rationale to choose such criteria was based on the significant findings of frontal region in our previous report,[22] Quick Inventory for Depressive Symptoms-Self Rating 16-item version (QIDS-SR16)[23] score >19, Hamilton Rating Scales for Depression 17-item (HDRS) score[24] >20, Hamilton Rating Scales for Anxiety (HARS) score[25] <5; no previous cognitive behavioral therapy or other psychotherapies; and no past history of claustrophobia or discomforts while receiving magnetic resonance (MR) scanning. The healthy controls (mostly from hospital staff) had no mental disorders, significant medical illnesses, or family history of first-degree relatives for depression. This open-label protocol of aripiprazole monotherapy in MDD was approved by the Institute of Review Board, Buddhist Tzu-Chi Hospital, Taipei Branch. There was no placebo-controlled group in the approved protocol. All participants signed the informed consent to receive the open-label aripiprazole monotherapy and MR scanning at baseline and at sixth week. The format and content of informed consent were approved by the Institute of Review Board, Buddhist Tzu-Chi Hospital, Taipei Branch. At the time of the MR imaging, none of the participants received benzodiazepine to relieve MR scanning-related anxiety. Handedness was determined by using the Edinburgh Inventory of Handedness.[26] All patients in the study received initial dose of aripiprazole as 3.75 mg per day. Then the dose was titrated to 7.5 mg per day from second to sixth week. The arbitrary dosage selection was based on our previous explorative experiences. The approved additional medication was lorazepam 0.5 to 1 mg/d only in case of insomnia or pre-sleeping anxiety. The partial response criterion was set as 25% reductions in the HDRS scores[27] after treatment of aripiprazole.

None of the controls received aripiprazole in this study.

2.2. MR imaging procedure and data acquisition

The MR imaging scans of brain structures were obtained using the 3-Tesla Siemens version scanners (TRIO, Siemens Magnetom, Germany) housed in the MR Center at the National Yang Ming University. Scans with 3-dimensional fast spoiled gradient-echo recovery (3D-FSPGR) T1W1 (TR 25.30ms; TE 3.03ms; slice thickness =1mm [no gap]; 192 slices; matrix =224 × 256; field of view: 256 mm; number of excitation =1) were performed on the patients and controls at baseline and at sixth week.

2.3. VBM processing and statistical analysis

2.3.1. Preprocessing. After manually reorienting and centering the images on the anterior commissure, data were processed based on the optimized VBM approach. The SIENAX tool (Structural Image Evaluation, using Normalization, of Atrophy)[28] was used to calculate total GMV (from spatially normalized images to make images comparable in normalized space) for each participant. Structural MR images were also...
processed with the FSLVBM [http://www.fmrib.ox.ac.uk/fsl/fslvbm/, version 1.1] function of FSL (FMRIB Software Library; version 4.1.1) to compare the differences in the GMV between patients and healthy controls. The theory of the FSLVBM method consists of 4 major steps. First, brain skull and other nonbrain tissues were removed by “Brain Extraction Tool” (version 2.1) to discard the nonbrain tissues in the subsequent analysis. Second, FSL Automated Segmentation Tool (version 4) performed tissue-specific segmentation to produce partial volume images of gray matter, which were then affine registered to Montreal Neurological Institute 152 template. The registered images were averaged and concatenated to establish a study-specific 4D template of gray matter. Third, the brain would be nonlinearly registered to the above template, and all the registered images were visually inspected by Dr Lai to check on the quality of registration. All the segmented gray matter images were concatenated into a 4D multisubject concatenated image, which was modulated by Jacobian of the warp field. The modulated 4D image was smoothed by Gaussian kernels (sigma 3mm in FSLVBM protocol), which approximately equals to full width at half maximum 7.5mm. On the other hand, a FSLVBM gray matter mask was created by unsmoothed segmentations and discard the nonbrain tissues in the subsequent analysis. Second, a FSLVBM grey matter mask was created by unsmoothed segmentations and unmodulated normalized segmentations. The smoothed 4D modulated image and gray matter mask were necessary for the following steps of permutations.

2.3.2. Estimated model and contrasts. A nonparametric inference (Randomize function of FSL, version 2.1) was used to calculate voxel-wise P values. Then we used the Threshold-Free Cluster Enhancement (TFCE)—a new method for finding clusters in data without defining an initial cluster-forming threshold or excessive smoothing.

We initially performed the F test to examine time × group interaction, and found significant interaction between time and group (corrected P < 0.05). Then a post hoc test was used under the impression of significant clusters found in the above F test. It was used to compare the differences in GMV using the following contrasts: “patients versus controls at baseline (mean week 0)” (for the GMV characteristics of MDD), “posttreatment versus pretreatment” (for the “state-dependent brain changes” related to the response in depression under aripiprazole monotherapy), “controls: week 6 versus week 0” (to investigate physiological and scanner-related changes in GMV), “patients versus controls at week 6” (for the “residual-deficit brain regions” that occurred in MDD even after partial response). Our model estimation used nonparametric computations, which were based on the randomized function of the FSL software. The randomized function also used a general linear model for permutations. For the pretreatment and posttreatment comparisons, we used the paired t test of randomized function to gain power. An independent-sample t test of randomized function was used to compare patients with controls. The method was comparable to multiple comparisons of random field theory. We included age, sex, total GMV, duration of illness status, and educational years as nuisance variables in the general linear model. The reasons to choose the above covariates were based on the possible aging effects on the prefrontal and temporal lobes, the sex effects on GMV, total GMV to control for individual variations in GMV, the association of longer illness duration with lower GMV, and the education-related intelligence would influence the gray matter of cerebral cortex. A supplementary analysis of general linear model without any covariate was also performed.

2.3.3. Statistical criteria of significance. We used family-wise error (FWE)-corrected method to obtain results for continuous random processes to find P values. With regards to the significance threshold, we defined a TFCE-corrected image thresholded at FWE-corrected P < 0.05. The threshold number of voxels for all contrast models was 20, and the significant clusters were defined as the voxels greater than 20.

2.3.4. SPSS analysis of correlations and differences between groups. The changes in the scores of clinical rating scales (the HDRS and the QIDS-R-16) between baseline and the sixth week were investigated by Wilcoxon signed-rank test, with the significance threshold set as P < 0.05. We also correlated the changes in total GMV to the changes in the HDRS scores using Spearman rank-correlation test. All tests were performed using SPSS version 17.

3. Results

3.1. Enrolled subjects

Nineteen patients were enrolled and all signed the informed consents. All patients were of Taiwanese (Han Chinese) origin. Among the 19 patients, 4 patients refused to continue aripiprazole monotherapy due to intolerable and persistent side effects (e.g., dizziness, fatigue, tiredness, sedation, akathisia, etc.). Therefore, 15 patients completed the trial to reach partially responding status in 6 weeks, and 27 healthy controls were enrolled (Table 1). The 15 patients and 27 controls received the acquisitions of MR imaging (without any benzodiazepine use) at baseline and at sixth week. No significant differences in ages, sex, and educational years were noted (Table 1). There were significant differences in HDRS and QIDS scores between patients and controls (Table 1).

### Table 1
Demographic data of patients and controls.

|                      | Patients (n = 15) | Controls (n = 27) | Sig. P (2-tailed) |
|----------------------|------------------|-------------------|------------------|
| Age, mean (SD), y    | 37.46 (5.93)     | 38.29 (11.80)     | 0.927            |
| Sex (number)         | F (9), M (6)     | F (15), M (12)    | 0.355            |
| Duration of illness, mean (SD), mos | 4.20 (2.07)     | 0 (0)             | N/A              |
| Educational years, mean (SD) | 15.61 (9.92)    | 15.92 (6.7)       | 0.072            |
| Handedness           | R (19)           | R (27)            | N/A              |
| HDRS, mean (SD)      | 21.73 (2.37)     | 1.37 (0.88)       | ≤ 0.001          |
| QIDS, mean (SD)      | 20.80 (3.66)     | 2.26 (1.13)       | ≤ 0.001          |

Sig. P (significance of P value) was from Mann-Whitney U test for nonparametric independent 2-sample t test.

F = female, HDRS = Hamilton Rating Scales for Depression 17-item; M = male; N = number; N/A = not applicable, QIDS = Quick Inventory of Depressive Symptoms—Self-rating 16-item version, SD = standard deviation.
3.2. Clinical data
All the 15 patients had improvements of MDD symptoms after a 6-week therapy of aripiprazole monotherapy. The depression symptoms improved significantly within 6 weeks (Wilcoxon signed-rank test, post hoc correction; scales: standard error; 95% confidence interval; CGI-S: 0.17: 1.57–2.28 [2-tailed \(P = 0.001\)]; HDRS: 0.82: 5.92–9.27 [2-tailed \(P = 0.001\)]; QIDS: 0.67: 6.35–9.11 [2-tailed \(P = 0.001\)]. The mean scores of HDRS (baseline: 21.73 ± 2.37 ≥ sixth week: 14.13 ± 2.09) and QIDS (baseline: 20.80 ± 2.36 ≥ sixth week: 13.06 ± 1.09) significantly decreased, respectively. It represented that these patients had partial response in the MDD symptoms and life qualities after the aripiprazole monotherapy as 7.5 mg/d in dose.

3.3. Brain GMV and FSLVBM data
The MDD patients had lower GMV in the right superior frontal gyrus (SFG) and left middle frontal gyrus (MFG) when compared with healthy controls at baseline (Fig. 1A, FEW-corrected \(P < 0.05\)). The patients had subtle increases in the GMV of left MFG and left superior parietal gyrus (SPG) after partial response (Fig. 1C and Table 2: FEW-corrected \(P < 0.05\)). In addition, patients had decreased GMV in the right inferior orbitofrontal gyrus (IOFG) and right inferior temporal gyrus (ITG) after partial response (Fig. 1D and Table 2: FEW-corrected \(P < 0.05\)). There were residual-deficit brain regions (residual GMV deficits) in right SFG of partially responding patients with MDD after aripiprazole monotherapy (Fig. 1B and Table 3: FEW-corrected \(P < 0.05\)). The partially responding patients with MDD did not have greater GMV than the controls. The supplementary analysis without covariate adjustment showed similar results of GMV deficits and “residual-deficit brain regions,” except for “state-dependent brain changes” without reductions of the ITG after partial response (Supplementary Fig. 1, http://links.lww.com/MD/B222). The total GMV was negatively correlated with the scores of HDRS \((r = −0.596; \text{Spearman rho } P = 0.014\)). Moreover, a positive correlation between the changes in HDRS scores and the changes in total GMV was found \((r = 0.583; \text{Spearman rho } P = 0.023\). No significant correlation between QIDRS-16 and the changes in total GMV was observed.

3.4. The repeated testing in control group
There were no significant MR imaging interscan biases (anatomical landmark displacement between 2 scans at baseline)
and at sixth week) and no significant changes in GMV within 6 weeks in the control group, for “baseline versus sixth week” and “sixth week versus baseline” (contrast E and F).

4. Discussion

In this study, we found that aripiprazole monotherapy might improve the symptoms of depression. In addition, partially responding patients with MDD had subtle decreases in the GMV of left MFG and SPG, and decreases in the GMV of right IOFG and ITG. The correlation between the increases in GMV and the improvements in clinical symptoms probably supported the theory of “state-dependent brain changes” for aripiprazole monotherapy. However, the GMV deficits of right SFG still remained even after partial response, which might represent “residual-deficit brain regions.”

The possible bias related to educational years (intelligence) should be noted. The intelligence has significant and widespread impacts on cerebral cortex. The inclusion of education covariate can exclude the possible bias related to education and intelligence. Our results were also in line with recent findings of the GMV increases in frontal lobe after antidepressant treatment.[10,11,38,39] In addition to the frontal lobe, these recent reports showed significant increases in the GMV of temporal and parietal lobes.[10,38,39] The short-term study results supported that the neuroplasticity of MDD could occur in such a short time course. However, our report showed significant decreases in the GMV of right IOFG and ITG combined with significant increases in the left MFG and SPG. We hypothesized this pattern of modulations in the GMV might be specific to antipsychotic characteristics of aripiprazole. However, the current study design would suffer from the lack of second patient group which should show a similar decline in depressive symptoms but without aripiprazole intervention. The design pitfall would limit us to find the specific modulations of GMV related to aripiprazole due to lack of comparison between aripiprazole and other typical treatments for MDD, such as antidepressants. In addition, the design of exploratory study would limit the interpretation of changes in GMV after aripiprazole therapy and it might be related to the adverse effects of aripiprazole. Further study with well-controlled design and region-of-interest, based on previous literature, is needed to compare the different effects between antidepressants and antipsychotics in MDD to confirm such specific pattern.

The GMV deficits of frontal cortex have been reported in several articles of MDD. Abe et al[5] found that patients with MDD might have GMV deficits in fronto-temporo-limbic regions, which also included the MFG. Our study also replicated the findings of Leung et al[40] who found that MDD patients had attention bias-related gray matter decreases in the right SFG. The SFG is also a part of “hate circuit,” which involve the pathogenesis of depression symptoms, risk and action responses, attention, reward, and emotion.[41] The above studies supported our results of GMV deficits in the SFG and MFG for patients with MDD at baseline status.

The increases in GMV of the MFG after aripiprazole monotherapy suggested that MDD patients might reverse the GMV deficits of the MFG after treatment. The remitted MDD patients would have less decline of GMV in the pretreatment cortex than nonremitted patients.[42] The subtle increases of GMV in the MFG might suggest compensatory mechanisms of aripiprazole in the GMV deficits. The increases in GMV of the SPG were out of our expectations. However, the GMV of the parietal lobe might represent a predictor of treatment response for MDD and interact with clinical severity.[43] Reduced serotonin synthesis in the SPG is specific for depression pathophysiology.[44] The changes in GMV of the MFG might represent a kind of “state-dependent brain changes” for MDD under aripiprazole treatment. In addition, the aripiprazole alters the regional cerebral blood flow of the frontal-parietal-temporal regions[45] and has high affinity for serotonin 5-HT1A receptors in the parietal cortex.[46] The modulating effects of aripiprazole for the cerebral blood flow and serotonin 5-HT1A high affinity probably play a role in the explanation of our results.

The decreases in the GMV of right IOFG and right ITG raised another issue for the aripiprazole monotherapy in MDD. The reduced GMV of orbitofrontal cortex has been found in patients with MDD.[47,48] The decreased GMV of right IOFG might be related to aripiprazole-related reductions in binding potential of serotonin 5-HT1A receptors in the orbitofrontal regions[49] and modulations of regional cerebral blood flows in the temporal regions.[50] The findings of right IOFG and ITG in our study were also different from those of antidepressant treatment, which showed no significant decreases in the GMV after remission.[5,9,10,39] An opposite effect in fronto-parietal regions (MFG and SPG) and fronto-temporal regions (IOFG and ITG) might suggest that low dose of aripiprazole seems more beneficial for the fronto-parietal regions (cognitive network)[50] than the fronto-temporal regions.[51]

Table 2

| GMV changes after a 6-week therapy of aripiprazole. |
|---------------------------------------------------|
| Posttreatment ≥ pretreatment (corrected P < 0.05) | MNI coordinate (peak voxel) | Cluster voxels | T value (peak voxel) |
|---------------------------------------------------|
| Left SFG                                           | (−14, −46, 78)              | 22             | 5.85                |
| Left MFG                                          | (−32, 32, 16)               | 39             | 6.13                |
| Right IOFG                                        | (54, −24, −6)               | 24             | 5.98                |
| Right ITG                                         | (56, −68, −2)               | 35             | 6.02                |

Table 3

| GMV differences between patients and controls at follow-up. |
|-------------------------------------------------------------|
| Controls > patients (corrected P < 0.05) | MNI coordinate (peak voxel) | Cluster voxels | T value (peak voxel) | Patients > controls (corrected P < 0.05) |
|-------------------------------------------------------------|
| Right SFG                                                   | (16, 4, 64)                 | 421            | 6.87                | No significant voxels                   |
The possible association between aripiprazole and changes in GMV were also an important finding in the current study. The chronic treatment of aripiprazole might induce differential expression of gene, chromatic remodeling, and transcription regulation in rat frontal cortex. The aripiprazole treatment would also increase brain-derived neurotrophic factor, glycogen synthase kinase 3 beta, and B-cell lymphoma-2 phosphorylation, which can induce further neurogenesis. Aripiprazole can also affect cognitive function and frontal metabolism due to higher D2 receptor occupancy. The changing effects of GMV might also be related to the following reasons, such as synaptic remodeling and neurogenesis from the stimulation of neurotrophic factors by antipsychotics, prevention of oxidative stress or 6-OH-dopamine lesioning and with subsequent increased proliferation of glial cells in the frontal cortex, and modulation of glutamate receptor function. The serotonin system might be stabilized due to the aripiprazole-related 5-HT1A partial agonism and 5-HT2C antagonism effects. Serotonergic and dopaminergic actions of aripiprazole might help MDD symptoms improve, which might be related to GMV changes of patients with MDD.

The residual GMV deficits of SFG might suggest that aripiprazole treatment could not reverse the GMV deficits in this region. The GMV deficits of SFG also have been reported in several VBM studies. The findings of residual GMV deficits might suggest that SFG represents the “residual-deficit brain regions” for patients with MDD under aripiprazole treatment. It also replicated our previous study of residual GMV deficits after antidepressant treatment. From the current results, we suggested pure MDD patients might have residual GMV deficits under aripiprazole treatment, and the SFG might be the specific region for the “residual-deficit brain regions” for partially responding patients with MDD under aripiprazole treatment. However, we still need further well-controlled and organized studies to confirm our findings in the SFG.

4.1. Limitations

Our study has several limitations: an open-label aripiprazole monotherapy study, a relatively inadequate sample size of patients, and a lack of placebo-controlled group limited the interpretation of the treatment effects in brain structures; aripiprazole may not directly be related to the GMV changes and the increase in the GMV may be totally unrelated to MDD; placebo intake by patients or aripiprazole intake by controls was not applied in the current study, which might limit the ideal explanation of our results. However, these control conditions may not be feasible due to ethical reasons.

5. Conclusions

To our knowledge, it is the first study to investigate aripiprazole monotherapy for MDD and related GMV changes. The changes in the GMV of fronto-parieto-temporal regions and residual GMV deficits in the SFG might represent “state-dependent brain changes” and “residual-deficit brain regions,” respectively, for aripiprazole monotherapy in MDD.

References

[1] van Tol MJ, van der Wee NJ, van den Heuvel OA, et al. Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry 2010;67:1002–11.
[2] Lai CH, Hsu YY. A subtle grey-matter increase in first-episode, drug-naive, non-psychotic major depressive disorder after 6 weeks’ duloxetine therapy. Int J Neuropsychopharmacol 2011;14:225–35.
[3] Lai CH, Hsu YY, Wu YT. First episode drug-naive major depressive disorder with panic disorder: gray matter deficits in limbic and default network structures. Eur Neuropsychopharmacol 2010;20:676–82.
[4] Zhao YJ, Du MY, Huang XQ, et al. Brain grey matter abnormalities in medication-free patients with major depressive disorder: a meta-analysis. Psychol Med 2014;44:2927–37.
[5] Abe O, Yamase H, Kasai K, et al. Voxel-based analyses of gray/white matter volume and diffusion tensor data in major depression. Psychiatry Res 2010;181:64–70.
[6] Ballmaier M, Toga AW, Blandon RE, et al. Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. Am J Psychiatry 2004;161:99–108.
[7] Li CT, Lin CP, Chou KH, et al. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuropsychiatry 2010;50:347–56.
[8] Yuan Y, Zhu W, Zhang Z, et al. Regional gray matter changes are associated with cognitive deficits in remitted geriatric depression: an optimized voxel-based morphometry study. Biol Psychiatry 2008;64:541–4.
[9] Lai CH, Wu YT. Duloxetine’s modest short-term influences in subcortical structures of first episode drug-naive patients with major depressive disorder and panic disorder. Psychiatry Res 2011;194:157–62.
[10] Phillips JL, Batten LA, Aldosary F, et al. Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression. J Clin Psychiatry 2012;73:623–5.
[11] Smith R, Chen K, Baxter L, et al. Antidepressant effects of sertraline associated with volume increases in dorsolateral prefrontal cortex. J Affect Disord 2013;146:414–9.
[12] Nickl-Jockschat T, Palomero Gallagher N, Kumar V, et al. Are morphological changes necessary to invade the therapeutic effects of electroconvulsive therapy? Eur Arch Psychiatry Clin Neurosci 2016;266:261–7.
[13] Ribezu SR, Duran F, Oliveira MC, et al. Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. PLoS One 2013;8:e80049.
[14] Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011;25:109–27.
[15] Pae CU, Patkar AA, Joon TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2007;24:322–6.
[16] Pae CU, Serretti A, Patkar AA, et al. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367–88.
[17] Lai CH. Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder. J Clin Psychopharmacol 2010;30:474–6.
[18] Lai CH. Aripiprazole-induced gray matter growth in a patient with major depressive disorder with panic disorder. J Clin Psychiatry 2010;71:360–2.
[19] Lai CH. Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naive non-psychotic major depressive disorder. J Neuropsychiatry Clin Neurosci 2012;24:E49–50.
[20] Ventura J, Liberman RP, Green MF, et al. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-IP); Psychiatry Res 1998;79:163–73.
[21] Clark SL, Souza RP, Adkins DE, et al. Genome-wide association study of patient-rated and clinician-rated global impression of severity during antidepressive treatment. Pharmacogenet Genomics 2013;23:69–77.
[22] Lai CH, Wu YT. Frontal-insula gray matter deficits in first-episode medication-naive patients with major depressive disorder. J Affect Disord 2014;160:74–9.
[23] Bernstein IH, Wendt B, Nasr SJ, et al. Screening for major depression in primary care. J Psychiatr Pract 2009;15:87–94.
[24] Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:36–62.
[25] Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–5.
[26] Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97–113.
Seidman LJ, Biederman J, Liang L, et al. Gray matter alterations in adults

Luders E, Narr KL, Thompson PM, et al. Mapping cortical gray matter in

Tisserand DJ, van Boxtel MP, Pruessner JC, et al. A voxel-based

Tao H, Guo S, Ge T, et al. Depression uncouples brain hate circuit. Mol Psychiatry 2013;18:101–11.

Tisserand DJ, van Boxtel MP, Pruessner JC, et al. A voxel-based morphometric study to determine individual differences in gray matter density associated with age and cognitive change over time. Cereb Cortex 2004;14:96–73.

Luders E, Narr KL, Thompson PM, et al. Mapping cortical gray matter in the young adult brain: effects of gender. Neuroimage 2005;26:493–501.

Lampe IK, Hulshoff Pol HE, Janssen J, et al. Association of depression duration with reduction of global cerebral gray matter volume in female patients with recurrent major depressive disorder. Am J Psychiatry 2003;160:2052–4.

Haier RJ, Jung RE, Yeo RA, et al. Structural brain variation and general intelligence. Neuroimage 2004;23:425–33.

Gong QY, Sluming V, Mayes A, et al. Voxel-based morphometry and stereology provide convergent evidence of the importance of medial prefrontal cortex for fluid intelligence in healthy adults. Neuroimage 2005;25:1175–86.

Narr KL, Woods RP, Thompson PM, et al. Relationships between IQ and regional cortical gray matter thickness in healthy adults. Cereb Cortex 2007;17:2163–71.

Marano CM, Workman CL, Lyman CH, et al. Structural imaging in late-life depression: association with mood and cognitive responses to antidepressant treatment. Am J Geriatr Psychiatry 2015;23:4–12.

Zeng LL, Shen H, Liu L, et al. State-dependent and trait-related gray matter changes in nonrefractory depression. Neuroreport 2015;26:57–65.

Leung KK, Lee TM, Wong MM, et al. Neural correlates of attention biases of people with major depressive disorder: a voxel-based morphometric study. Psychol Med 2009;39:1097–106.

Tao H, Guo S, Ge T, et al. Depression uncouples brain hate circuit. Mol Psychiatry 2013;18:101–11.

Frodl TS, Koutsouleris N, Bottlender R, et al. Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry 2008;65:1156–65.

Soriano-Mas C, Fernandez-Ribas R, Pujol J, et al. Cross-sectional and longitudinal assessment of structural brain alterations in melancholic depression. Biol Psychiatry 2011;69:318–25.

Rosa-Neto P, Diksic M, Okazawa H, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004;61:556–63.

Handley R, Zelaya FO, Reinders AA, et al. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Hum Brain Mapp 2013;34:272–82.

Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007;190:373–82.

Monkul ES, Hatch JP, Nicollot MA, et al. Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. Mol Psychiatry 2007;12:360–6.

Vasc N, Walter H, Hose A, et al. Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study. J Affect Disord 2008;109:107–16.

Lerod J, Lothe A, Ryelin P, et al. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. J Clin Psychopharmacol 2013;33:84–9.

Borst JP, Anderson JR. Using model-based functional MRI to locate working memory updates and declarative memory retrievals in the fronto-parietal network. Proc Natl Acad Sci U S A 2013;110:1628–33.

Mulert C, Kirsch V, Whford TJ, et al. Hearing voices: a role of interhemispheric auditory connectivity? World J Biol Psychiatry 2012;13:133–8.

Cheng MC, Liao DL, Hsiung CA, et al. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol 2008;11:207–16.

Park SW, Lee JG, Ha EK, et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 2009;19:536–62.

Yoshimura R, Hori H, Ikemouchi-Sugita A, et al. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 2012;27:33–8.

Kim E, Howes OD, Turkheimer FE, et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A dural [11C]raclopride and [18F]FDG imaging study with aripiprazole. Psychopharmacology (Berl) 2012.

Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001;50:729–42.

Parikh V, Khan MM, Mahadik SP. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004;356:135–9.

Wang HD, Dunnivant FD, Jarman T, et al. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004;29:1230–8.

Duncan GE, Miyamoto S, Leipag JN, et al. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 2000;293:8–14.

Vergne DE, Anton RF. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Drug Targets 2010;9:50–4.

Frodl T, Scheuerecker J, Albrecht J, et al. Neuronal correlates of emotional processing in patients with major depression. World J Biol Psychiatry 2009;10:202–8.